Nicotinell Fruit 2mg medicinska tuggummi

Nicotinell is a globally recognized brand specializing in Nicotine Replacement Therapy (NRT) products, designed to assist individuals in quitting or reducing smoking. This specific product, Nicotinell Fruit 2mg, is a medicated chewing gum that delivers a controlled amount of nicotine to the bloodstream through the oral mucosa, helping to alleviate withdrawal symptoms such as cravings, irritability, and restlessness.

Historically part of the consumer healthcare divisions of major pharmaceutical companies like Novartis and later GlaxoSmithKline (GSK), the brand was part of a major industry shift in the early 2020s. In 2022, GSK and Pfizer spun off their combined consumer healthcare businesses to form Haleon, which initially held ownership of the Nicotinell portfolio.

In a significant development finalized in September 2024, Haleon divested its global NRT business outside the United States—including Nicotinell—to the Indian pharmaceutical giant Dr. Reddy’s Laboratories. As of 2026, the brand is owned by Dr. Reddy's through its Swiss and Swedish subsidiaries. Manufacturing for the global market is conducted in multiple international locations, often involving specialized facilities in Europe and India to maintain medical-grade production standards.